File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization

TitleComparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization
Authors
Issue Date2006
PublisherAmerican Medical Association. The Journal's web site is located at http://www.archsurg.com
Citation
Archives Of Surgery, 2006, v. 141 n. 12, p. 1231-1236 How to Cite?
AbstractHypothesis: The survival benefits of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) are similar for patients with unresectable hepatocellular carcinoma amenable to either treatment. Design: Retrospective comparative study. Setting: Tertiary care institution. Patients: From February 22, 2001, to March 10, 2004, 91 patients with unresectable hepatocellular carcinoma (tumor diameter <5 cm and <4 tumor nodules) treated by either TACE or RFA were analyzed from a prospective database. Main Outcome Measures: The treatment-related morbidity, mortality, overall survival, and time to disease progression. Results: Forty patients received TACE and 51 patients received RFA during the study period. Demographic data were comparable in both groups of patients. The treatment-related morbidities of TACE and RFA were 10% and 28%, respectively (P = .04). There was no treatment-related mortality in either group. There was 1 patient (2%) with complete tumor remission in the TACE group, and the complete ablation rate in the RFA group was 96%. The time to disease progression was similar in both groups (P = .95). The overall survival rates at 1 and 2 years were 80% and 58%, respectively, in the TACE group and 82% and 72%, respectively, in the RFA group (P = .21). Conclusions: The overall survival and time for disease progression were similar in both groups of patients. In terms of the survival result, the efficacies of RFA and TACE were comparable for patients with unresectable hepatocellular carcinoma. ©2006 American Medical Association. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/83790
ISSN
2014 Impact Factor: 4.926
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChok, KSHen_HK
dc.contributor.authorNg, KKen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorChi, MLen_HK
dc.contributor.authorYuen, Jen_HK
dc.contributor.authorWai, KTen_HK
dc.contributor.authorSheung, TFen_HK
dc.date.accessioned2010-09-06T08:45:15Z-
dc.date.available2010-09-06T08:45:15Z-
dc.date.issued2006en_HK
dc.identifier.citationArchives Of Surgery, 2006, v. 141 n. 12, p. 1231-1236en_HK
dc.identifier.issn0004-0010en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83790-
dc.description.abstractHypothesis: The survival benefits of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) are similar for patients with unresectable hepatocellular carcinoma amenable to either treatment. Design: Retrospective comparative study. Setting: Tertiary care institution. Patients: From February 22, 2001, to March 10, 2004, 91 patients with unresectable hepatocellular carcinoma (tumor diameter <5 cm and <4 tumor nodules) treated by either TACE or RFA were analyzed from a prospective database. Main Outcome Measures: The treatment-related morbidity, mortality, overall survival, and time to disease progression. Results: Forty patients received TACE and 51 patients received RFA during the study period. Demographic data were comparable in both groups of patients. The treatment-related morbidities of TACE and RFA were 10% and 28%, respectively (P = .04). There was no treatment-related mortality in either group. There was 1 patient (2%) with complete tumor remission in the TACE group, and the complete ablation rate in the RFA group was 96%. The time to disease progression was similar in both groups (P = .95). The overall survival rates at 1 and 2 years were 80% and 58%, respectively, in the TACE group and 82% and 72%, respectively, in the RFA group (P = .21). Conclusions: The overall survival and time for disease progression were similar in both groups of patients. In terms of the survival result, the efficacies of RFA and TACE were comparable for patients with unresectable hepatocellular carcinoma. ©2006 American Medical Association. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherAmerican Medical Association. The Journal's web site is located at http://www.archsurg.comen_HK
dc.relation.ispartofArchives of Surgeryen_HK
dc.titleComparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolizationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0004-0010&volume=141&issue=12&spage=1231&epage=1236&date=2006&atitle=Comparable+survival+in+patients+with+unresectable+hepatocellular+carcinoma+treated+by+radiofrequency+ablation+or+transarterial+chemoembolizationen_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1001/archsurg.141.12.1231en_HK
dc.identifier.pmid17178966-
dc.identifier.scopuseid_2-s2.0-33845643748en_HK
dc.identifier.hkuros125530en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33845643748&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume141en_HK
dc.identifier.issue12en_HK
dc.identifier.spage1231en_HK
dc.identifier.epage1236en_HK
dc.identifier.isiWOS:000242669500017-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChok, KS=6508229426en_HK
dc.identifier.scopusauthoridNg, KK=7403179075en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.scopusauthoridChi, ML=8343493900en_HK
dc.identifier.scopusauthoridYuen, J=7102620431en_HK
dc.identifier.scopusauthoridWai, KT=8696033500en_HK
dc.identifier.scopusauthoridSheung, TF=6506234707en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats